President & Chief Executive Officer
Jeff Hatfield joined Vitae Pharmaceuticals as President, Chief Executive Officer and a member of the Board of Directors in March 2004. Since becoming CEO, he has successfully transitioned Vitae from a novel technology start-up to a thriving product-focused discovery and development engine with a robust pipeline that includes multiple programs advancing in human clinical trials. Mr. Hatfield has focused the company on high value therapeutic areas with significant global unmet medical need, including diabetes, Alzheimer’s disease, autoimmune disorders, acute coronary syndrome, atopic dermatitis and immuno-oncology. Notably, since joining the company Mr. Hatfield has grown shareholder value in a uniquely capital efficient way – Vitae’s last venture round dates back to 2004, his first year with the company.
Prior to joining Vitae Pharmaceuticals, Mr. Hatfield worked at Bristol-Myers Squibb in a variety of executive positions, including: Senior Vice President of BMS’s Virology and Immunology Divisions, where he was responsible for all aspects of the $1 billion business; President and General Manager, Canada; and, Vice President, U.S. Managed Health Care. While at BMS, Mr. Hatfield was directly associated with several product successes, including Pravachol®, Plavix®, Avapro®, Abilify®, Reyataz® and Atripla®.
Mr. Hatfield holds an M.B.A. from The Wharton School, University of Pennsylvania and a bachelor’s degree in Pharmacy from Purdue University, where he is a Distinguished Alumni. He is a member of the Board of Directors of the Biotechnology Industry Organization (BIO), serving on the Executive Committee of the Emerging Company Section. He is a board member of Ambit Biosciences, and is also a member of the Advisory Committees for Purdue University’s College of Pharmacy, Drexel University’s LeBow College of Business and the Chapman-KGI School of BioPharmacy.